Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Depreciation & Amortization (CF) (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Depreciation & Amortization (CF) for 4 consecutive years, with $114000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 11.63% to $114000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $503000.0 through Dec 2025, down 5.45% year-over-year, with the annual reading at $503000.0 for FY2025, 5.45% down from the prior year.
  • Depreciation & Amortization (CF) hit $114000.0 in Q4 2025 for Axsome Therapeutics, down from $120000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $149000.0 in Q1 2025 to a low of $37000.0 in Q1 2022.
  • Historically, Depreciation & Amortization (CF) has averaged $109812.5 across 4 years, with a median of $120000.0 in 2025.
  • Biggest five-year swings in Depreciation & Amortization (CF): surged 143.24% in 2023 and later fell 14.29% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $85000.0 in 2022, then surged by 56.47% to $133000.0 in 2023, then dropped by 3.01% to $129000.0 in 2024, then fell by 11.63% to $114000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for AXSM at $114000.0 in Q4 2025, $120000.0 in Q3 2025, and $120000.0 in Q2 2025.